Dr. Martens (LON:DOCS) Reaches New 52-Week High Following Analyst Upgrade

Dr. Martens plc (LON:DOCS)’s stock price hit a new 52-week high during trading on Tuesday after Peel Hunt upgraded the stock to a buy rating. The stock traded as high as GBX 86 ($1.16) and last traded at GBX 85.54 ($1.15), with a volume of 1096627 shares traded. The stock had previously closed at GBX 81.05 ($1.09).

DOCS has been the subject of several other reports. Royal Bank Of Canada cut their price target on Dr. Martens from GBX 7,000 to GBX 6,000 and set a “sector perform” rating for the company in a report on Monday, May 19th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Dr. Martens in a report on Friday, July 11th. One investment analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Dr. Martens currently has a consensus rating of “Hold” and an average price target of GBX 6,000.

Dr. Martens Trading Up 4.2%

The firm has a market capitalization of £819.81 million, a price-to-earnings ratio of 11.97, a P/E/G ratio of 6.40 and a beta of 0.11. The company has a debt-to-equity ratio of 127.27, a quick ratio of 1.13 and a current ratio of 2.85. The business has a fifty day moving average price of GBX 77.55 and a 200 day moving average price of GBX 65.44.

Dr. Martens (LON:DOCS) last released its quarterly earnings data on Thursday, June 5th. The company reported GBX 2.40 EPS for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. As a group, equities analysts forecast that Dr. Martens plc will post 2.5809394 earnings per share for the current year.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history.